Current status of glycemic control of patients with diabetes in Korea: The fifth Korea national health and nutrition examination survey

Diabetes and Metabolism Journal

Volumn 38, Issue 3, 2014, Pages 197-203

  Jeon, Ja Young ^a   Kim, Dae Jung ^a   Ko, Seung Hyun ^b   Kwon, Hyuk Sang ^b   Lim, Soo ^c   Choi, Sung Hee ^c   Kim, Chul Sik ^d   An, Jee Hyun ^e   Kim, Nan Hee ^e   Won, Jong Chul ^f   Kim, Jae Hyeon ^g   Cha, Bong Yun ^b   Song, Kee Ho ^h  

^a Ajou University School of Medicine   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Hallym University College of Medicine   (China)

^e Korea University College of Medicine   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h Konkuk University School of Medicine   (South Korea)

Author keywords

Diabetes mellitus; Glycemic control; Korea; Korea national health and nutrition examination survey

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH STATUS; HEALTH SURVEY; HUMAN; INSULIN TREATMENT; KOREA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; WAIST CIRCUMFERENCE;

EID: 84903836653     PISSN: 22336079     EISSN: 22336087     Source Type: Journal    
DOI: 10.4093/dmj.2014.38.3.197     Document Type: Article

References (15)

1. Statistics Korea: Causes of death statistics 2012. Available from: http://kostat.go.kr (updated 2013 Sep 25).
2. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011;378:169-81.
3. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81.
4. Jeon JY, Ko SH, Kwon HS, Kim NH, Kim JH, Kim CS, Song KH, Won JC, Lim S, Choi SH, Jang MJ, Kim Y, Oh K, Kim DJ, Cha BY; Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Prevalence of diabetes and prediabetes according to fasting plasma glucose and HbA1c. Diabetes Metab J 2013;37:349-57.
5. Choi YJ, Kim HC, Kim HM, Park SW, Kim J, Kim DJ. Prevalence and management of diabetes in Korean adults: Korea National Health and Nutrition Examination Surveys 1998-2005. Diabetes Care 2009;32:2016-20.
6. Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus of Korean Diabetes Association, Park IB, Kim J, Kim DJ, Chung CH, Oh JY, Park SW, Lee J, Choi KM, Min KW, Park JH, Son HS, Ahn CW, Kim H, Lee S, Lee IB, Choi I, Baik SH. Diabetes epidemics in Korea: reappraise nationwide survey of diabetes "diabetes in Korea 2007". Diabetes Metab J 2013;37:233-9.
7. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013;368:1613-24.
8. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B; Professional Practice Committee American Diabetes Association; European Association for the Study of Diabetes. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21.
9. Yu NC, Su HY, Chiou ST, Yeh MC, Yeh SW, Tzeng MS, Sheu WH. Trends of ABC control 2006-2011: a National Survey of Diabetes Health Promotion Institutes in Taiwan. Diabetes Res Clin Pract 2013;99:112-9.
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
11. Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218.
12. Walter H, Lubben G. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. Drugs 2005;65:1-13.
13. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab 2012;23:205-15.
14. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013;17:819-37.
15. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010;33:428-33.